GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-lin

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

GSK today announced positive results from the registrational phase I/II ARROS-1 trial